| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Devin Oglesbee, Ph.D., Director of the Biochemical and Molecular Genetics Laboratories at Mayo Clinic, provides an overview of the lysosomal storage disease panel, when it is appropriate to order this test, what actions the results allow you to take, and how this test improves upon previous approaches.
To ensure we continue to provide the highest level of value-based reference laboratory services, Mayo Medical Laboratories will be implementing a new pathology laboratory information system on Friday, Sept. 8, 2017. View the list of orderable pathology tests included in the system upgrade.
An algorithm is a step-by-step procedure to guide clinicians and laboratorians in appropriate laboratory test ordering.
The algorithm can be viewed here.
In May 2017, Mayo Medical Laboratories announced eight brand new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Clinical Laboratory News recently highlighted a Mayo Clinic study that shows how plasma ceramides may predict cardiovascular events in patients with or without coronary artery disease.
Useful For Assessing the patient’s probability of having detectable prostate cancer when total prostate specific antigen (PSA) concentrations are between 4–10 ng/mL. Results from a[...]
European Heart Journal recently highlighted Mayo Clinic's new blood test that may predict cardiovascular events in patients with or without coronary artery disease.
Detection of individuals with low thiopurine methyltransferase (TPMT) activity who are at risk for excessive myelosuppression or severe hematopoietic toxicity when taking thiopurine drugs.